• Weekly Pharma News Review | PharmaSources.com (0829-0902) PharmaSources.com
    September 06, 2022
    This week, the second biological drug developed by SinoCellTech - ripertamab, a new anti-CD20 monoclonal antibody, was approved for marketing, which aroused the attention of the industry. The news review of this week is from August 29 to September 2.
  • Weekly Pharma News Review | PharmaSources.com (0822-0826) PharmaSources.com
    August 29, 2022
    The EU officially released the eagerly anticipated final revision of its GMP Annex 1 for sterile drug products. The news review of this week is from August 22 to 26, covering a total of 20 pieces of information on drug review, R&D, business, and policy.
  • Weekly Pharma News Review | PharmaSources.com (0815-0819) PharmaSources.com
    August 23, 2022
    Alphamab Oncology’s JSKN003 injection became the first Chinese bispecific antibody ADC declared for clinical use. The news review of this week is from August 15 to 19, covering a total of 24 pieces of information on drug review, R&D, and business.
  • Weekly Pharma News Review | PharmaSources.com (0808-0812) PharmaSources.com
    August 17, 2022
    The FDA approved the supplementary new drug application for Bayer’s darolutamide in combination with docetaxel, which sparked widespread social attention. The news review of this week is from August 8 to 12, covering a total of 23 pieces of information.
  • Weekly Pharma News Review | PharmaSources.com (May. 23th - May. 29th) PharmaSources.com
    May 31, 2022
    This week, a steady flow of good news kept pouring into the Chinese pharmaceutical market. The local "first-in-class" Benvimod was successfully approved by FDA while Hengrui's SHR3680 tablets in treating prostate cancer had a successful Phase III clinical
  • Weekly Pharmaceutical News Review of PharmaSources.com (February 21st -25th) PharmaSources/Caicai
    February 28, 2022
    21st -25th Feb. is the statistical time for the weekly review that covers four sections, Review, R&D, Trading, Investment & Financing, and IPO, and contains 18 pieces of information.
PharmaSources Customer Service